Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUM229PE | TNBC | - | Cetuximab | EGFR | ErbB | 0.137 | uM | 9860.125 | 0.9929 | 0.9911 | 1.6001 | |
| SUM229PE | TNBC | - | Cetuximab | EGFR | ErbB | 0.685 | uM | 9860.125 | 0.9036 | 0.8773 | 1.6001 | |
| SUM52PE | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.00000175 | uM | 7923.018 | 0.7472 | 0.3861 | 0.7947 | |
| SUM52PE | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.00000877 | uM | 7923.018 | 0.8901 | 0.7275 | 0.7947 | |
| SUM52PE | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.0000438 | uM | 7923.018 | 0.6121 | 0.0783 | 0.7947 | |
| SUM52PE | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.000219 | uM | 7923.018 | 0.8700 | 0.6785 | 0.7947 | |
| SUM52PE | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.0011 | uM | 7923.018 | 0.7596 | 0.4150 | 0.7947 | |
| SUM52PE | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.00548 | uM | 7923.018 | 0.9778 | 0.9443 | 0.7947 | |
| SUM52PE | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.0274 | uM | 7923.018 | 1.2337 | 1.6050 | 0.7947 | |
| SUM52PE | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.137 | uM | 7923.018 | 0.7472 | 0.3861 | 0.7947 | |
| SUM52PE | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.685 | uM | 7923.018 | 0.7550 | 0.4042 | 0.7947 | |
| SUM52PE | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.00000175 | uM | 9878.006 | 0.9686 | 0.9549 | 1.3968 | |
| SUM52PE | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.00000877 | uM | 9878.006 | 1.0971 | 1.1372 | 1.3968 | |
| SUM52PE | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.0000438 | uM | 9878.006 | 0.9441 | 0.9193 | 1.3968 | |
| SUM52PE | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.000219 | uM | 9878.006 | 1.0531 | 1.0754 | 1.3968 | |
| SUM52PE | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.0011 | uM | 9878.006 | 0.5710 | 0.3391 | 1.3968 | |
| SUM52PE | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.00548 | uM | 9878.006 | 1.0508 | 1.0722 | 1.3968 | |
| SUM52PE | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.0274 | uM | 9878.006 | 1.0544 | 1.0773 | 1.3968 | |
| SUM52PE | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.137 | uM | 9878.006 | 0.9851 | 0.9786 | 1.3968 | |
| SUM52PE | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.685 | uM | 9878.006 | 0.9035 | 0.8598 | 1.3968 | |
| T47D | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.00000175 | uM | 9033.018 | 1.0242 | 1.0556 | 0.8708 | |
| T47D | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.00000877 | uM | 9033.018 | 0.9899 | 0.9768 | 0.8708 | |
| T47D | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.0000438 | uM | 9033.018 | 1.0820 | 1.1895 | 0.8708 | |
| T47D | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.000219 | uM | 9033.018 | 1.0654 | 1.1508 | 0.8708 | |
| T47D | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.0011 | uM | 9033.018 | 0.9890 | 0.9747 | 0.8708 |